PHASERX INC Financials (USD)
| Sales 2015 | 375K | Sales 2016 | - | Capitalization | 18.12M |
|---|---|---|---|---|---|
| Net income 2015 | -7M | Net income 2016 | -20M | EV / Sales 2015 * | - |
| Net Debt 2015 | 16.55M | Net cash position 2016 | 9.78M | EV / Sales 2016 | - |
| P/E ratio 2015 * |
-
| P/E ratio 2016 |
-0.58
x | Employees | - |
| Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.89% | 104B | |
| +2.03% | 97.42B | |
| +0.79% | 22.2B | |
| -17.78% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -15.65% | 15.06B | |
| +3.90% | 13.98B | |
| +35.02% | 11.66B |
